Silymarin Exerts Potent Antipruritic Effects Against Chloroquine-Induced Scratching in Mice by Modulating the NO/NF-κB/TRPA1 Pathway
Abstract
Background: Pruritus may occur through histamine-dependent or histamine-independent mechanisms. Chronic pruritus, which is often unresponsive to antihistamines, has been associated with nitric oxide (NO) signaling, which can modulate nuclear factor-κB (NF-κB) activity and transient receptor potential ankyrin 1 (TRPA1) function.
Objectives: This study investigated the antipruritic potential of silymarin in a mouse model of chloroquine-induced systemic pruritus.
Methods: Adult male NMRI mice were allocated to 16 groups. Treatments included silymarin (10, 30, and 60 mg/kg), L-NAME (1 and 10 mg/kg), aminoguanidine, L-arginine (10 and 100 mg/kg), sildenafil (10 and 20 mg/kg), and various combinations of these agents with silymarin. Scratching behavior, including frequency and duration, was recorded for 30 minutes on the second day after chloroquine (CQ) administration. Dorsal root ganglia (DRG) were analyzed by immunofluorescence to assess the expression of NF-κB and TRPA1.
Results: Silymarin (60 mg/kg), L-NAME (10 mg/kg), and aminoguanidine significantly reduced chloroquine-induced itching, whereas L-arginine (100 mg/kg) and sildenafil (20 mg/kg) exacerbated it. The combination of subeffective doses of L-NAME (1 mg/kg) and silymarin (10 mg/kg) produced potentiated antipruritic effects, whereas L-arginine and sildenafil counteracted the inhibitory effects of high-dose silymarin. CQ increased NF-κB and TRPA1 expression in the DRG. These changes were ameliorated by silymarin and…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.